

```

Set      Items  Description
S1      180606  LACTOBACILLUS
S2      12     S1 AND PROTEASE (1W) MATURATION (1W) PROTEIN
S3      12     RD (unique items)
? s lactobacillus and pmp
      180606  LACTOBACILLUS
      21468  PMP
      S4      16  LACTOBACILLUS AND PMP

```

? rd

```

>>>Duplicate detection is not supported for File 398.
>>>Duplicate detection is not supported for File 654.
>>>Duplicate detection is not supported for File 349.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 390.
>>>Duplicate detection is not supported for File 347.
>>>Duplicate detection is not supported for File 446.
>>>Duplicate detection is not supported for File 342.
>>>Duplicate detection is not supported for File 345.
>>>Duplicate detection is not supported for File 181.
>>>Duplicate detection is not supported for File 324.
>>>Duplicate detection is not supported for File 391.
>>>Duplicate detection is not supported for File 393.
>>>Duplicate detection is not supported for File 767.
>>>Duplicate detection is not supported for File 344.
>>>Duplicate detection is not supported for File 286.

```

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

```

      S5      15  RD (unique items)

```

? t s5/3,ab/1-15

>>>No matching display code(s) found in file(s): 65, 135, 181, 342, 345, 390-391, 398, 446, 767

5/3,AB/1 (Item 1 from file: 654)

DIALOG(R)File 654:US Pat.Full.

(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005551169

Derwent Accession: 2002-426107

Chlamydia %pmp% proteins, gene sequences and uses thereof

Inventor: Jackson, W., INV

Correspondence Address: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS,
NEW YORK, NY, 100362711

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040037846	A1	20040226	US 2003398248	20030801
PCT					

Fulltext Word Count: 40391

Abstract:

The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefrp, (%PMP%-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the %PMP% polypeptides and %PMP%-derived polypeptides and T-cells specific for %PMP% polypeptides and %PMP%-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising %PMP% polypeptides or %PMP%-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia

5/3,AB/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005494099

Derwent Accession: 2002-154726

Immunisation against chlamydia pneumoniae

Inventor: Ratti, Giuloi, INV

Grandi, Guido, INV

Correspondence Address: Rebecca Hale Chiron Corporation, Intellectual
Property Law Department R 3 PO Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20040005667	A1	20040108	US 2003312273	20030505
PCT					
Priority				GB 200016363	20000703
				GB 200017047	20000711
				GB 200017938	20000721
				GB 200019368	20000807
				GB 200020440	20000818
				GB 200022583	20000914
				GB 200027549	20001110
				GB 200031706	20001222

Fulltext Word Count: 46188

Abstract:

The published genomic of Chlamydia pneumoniae reveals over 1000 putative encoded proteins but does not itself indicate which of these might be useful antigens for immunisation and vaccination or for diagnosis. This difficulty is addressed by the invention, which provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.

5/3,AB/3 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

01114910

METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

METHODES ET ORGANISMES POUR LA PRODUCTION DE VITAMERES B6

Patent Applicant/Assignee:

BASF AKTIENGESELLSCHAFT, 67056 Ludwigshafen, DE, DE (Residence), DE
(Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

YOCUM Rogers R, 4 Orchard Lane, Lexington, MA 02420, US, US (Residence),
US (Nationality), (Designated only for: US)

WILLIAMS Mark K, 58 School Street, Revere, MA 02151, US, US (Residence),
US (Nationality), (Designated only for: US)

PERO Janice G, 20 Solomon Pierce Road, Lexington, MA 02420, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

HANLEY Elizabeth A (et al) (agent), Lahive & Cockfield, LLP, 28 State
Street, Boston, MA 02109, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200435010 A2 20040429 (WO 0435010)

Application: WO 2003US8880 20030321 (PCT/WO US03008880)

Priority Application: US 2002367089 20020322; US 2002367863 20020325; US
2002368618 20020329; US 2003451824 20030303

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG
SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 19530

English Abstract

The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms having increased activity of at least one B6 vitamer biosynthetic enzyme, e.g., YaaD or YaaE, or a homologue thereof, or Epd, PdxA, PdxJ, PdxF, PdxB, PdxH, and/or Dxs, or a homologue thereof.

French Abstract

La presente invention concerne des methodes de production de vitameres B6 consistant a cultiver un organisme surexprimant une enzyme qui catalyse une etape dans la biosynthese d'un vitamere B6 dans des conditions permettant la production d'un vitamere B6. La presente invention concerne en outre des methodes de production de vitameres B6 consistant a cultiver des micro-organismes recombinés presentant une activite accrue d'au moins une enzyme biosynthetic de vitamere B6, telle que YaaD ou YaaE, ou d'un homologue correspondant, ou de Epd, PdxA, PdxJ, PdxF, PdxB, PdxH et/ou Dxs, ou d'un homologue correspondant.

5/3,AB/4 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2005 WIPO/Univentio. All rts. reserv.

00994443

NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

NOUVEAUX ACIDES NUCLEIQUES ET POLYPEPTIDES

Patent Applicant/Assignee:

NUVELO INC, 675 Almanor Avenue, Sunnyvale, CA 94085, US, US (Residence),
US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

TANG Y Tom, 4230 Ranwick Court, San Jose, CA 95118, US, US (Residence),
US (Nationality), (Designated only for: US)

YANG Yonghong, 4230 Ranwick Court, San Jose, CA 95118, US, US (Residence),
CN (Nationality), (Designated only for: US)

WANG Zhi Wei, 1130 Founders Boulevard, Athens, GA 30606, US, US
(Residence), CN (Nationality), (Designated only for: US)

WENG Gezhi, 415 Moraga Avenue, Piedmont, CA 94611, US, US (Residence), US
(Nationality), (Designated only for: US)

MA Yunqing, 3670 Tamarack In., Apt 36, Santa Clara, CA 95051, US, US
(Residence), CN (Nationality), (Designated only for: US)

Legal Representative:

POLIZOTTO Renee (agent), Nuvelo, Inc., 675 Almanor Avenue, Sunnyvale, CA
94085, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200323013 A2-A3 20030320 (WO 0323013)

Application: WO 2002US29001 20020913 (PCT/WO US0229001)

Priority Application: US 2001322511 20010913; US 2002243552 20020912

Parent Application/Grant:

Related by Continuation to: US 2001322511 20010913 (CIP); US 2002243552
20020912 (CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications

prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 99574

English Abstract

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

French Abstract

L'invention concerne de nouveaux acides nucleiques, de nouvelles sequences polypeptidiques codees par ces acides nucleiques, et l'utilisation de ceux-ci.

5/3,AB/5 (Item 3 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

00895045

CHLAMYDIA %PMP% PROTEINS, GENE SEQUENCES AND USES THEREOF
PROTEINES %PMP% DE CHLAMYDIA, SEQUENCES DE GENE ET UTILISATION DE CELLES-CI
Patent Applicant/Assignee:

ANTEX BIOLOGICS INC, 300 Professional Drive, Gaithersburg, MD 20879, US,
US (Residence), US (Nationality), (For all designated states except:
US)

Patent Applicant/Inventor:

JACKSON W James, 1687 Armistice Way, Marriottsville, MD 21104, US, US
(Residence), US (Nationality), (Designated only for: US)

Legal Representative:

BALDWIN Geraldine F (et al) (agent), Pennie & Edmonds LLP, 1155 Avenue of
the Americas, New York, NY 10036, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200228998 A2-A3 20020411 (WO 0228998)
Application: WO 2001US30345 20010928 (PCT/WO US0130345)
Priority Application: US 2000677752 20001002

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK
SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 36905

English Abstract

The invention discloses the Chlamydia PMPE and PMPI polypeptide, polypeptides derived therefor, (%PMP%-derived polypeptides), nucleotide sequences encoding said polypeptides, antibodies that specifically bind the %PMP% polypeptides and %PMP%-derived polypeptides and T-cells specific for %PMP% polypeptides and %PMP%-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising %PMP% polypeptides or %PMP%-derived polypeptides or antibodies thereto. The invention

additionally discloses methods of inducing in animals an immune response to Chlamydia cells, Chlamydia elementary bodies, and/or cells expressing Chlamydial proteins, e.g., cell infected with Chlamydia.

French Abstract

La presente invention concerne le polypeptide PMPE et PMPI de chlamydia, des polypeptides derives de celui-ci (polypeptides derives de %PMP%), des sequences nucleotidiques codantes pour ces polypeptides, des anticorps qui se lient specifiquement a ces polypeptides %PMP% et a ces polypeptides derives de %PMP% et des lymphocytes T specifiques pour ces polypeptides %PMP% et ces polypeptides derives de %PMP%. Cette invention concerne aussi des compositions prophylactiques et therapeutiques, comprenant des composition immunogenes, par exemple des vaccins, comprenant ces polypeptides %PMP%, ces polypeptides derives de %PMP% ou des anticorps de ceux-ci. Cette invention concerne enfin des techniques permettant d'induire chez des animaux une reponse immunitaire des cellules a chlamydia, des corps elementaires de chlamydia, et/ou des cellules exprimant les proteines de chlamydia, par exemple une cellule infectee par chlamydia.

5/3,AB/6 (Item 4 from file: 349)
DIALOG(R) File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

00868740

IMMUNISATION AGAINST CHLAMYDIA PNEUMONIAE

IMMUNISATION CONTRE UNE INFECTION PAR CHLAMYDIA PNEUMONIAE

Patent Applicant/Assignee:

CHIRON S P A, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

RATTI Giulio, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)

GRANDI Guido, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)

Legal Representative:

HALLYBONE Huw George (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200202606 A2-A3 20020110 (WO 0202606)

Application: WO 2001IB1445 20010703 (PCT/WO IB0101445)

Priority Application: GB 200016363 20000703; GB 200017047 20000711; GB 200017983 20000721; GB 200019368 20000807; GB 200020440 20000818; GB 200022583 20000914; GB 200027549 20001110; GB 200031706 20001222

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 79446

English Abstract

The genomic of Chlamydia pneumoniae reveals over 1000 putative encoded proteins. The invention provides a number of C. pneumoniae protein sequences suitable for vaccine production and development and/or for diagnostic purposes.

French Abstract

La sequence genomique publiee de <i>Chlamydia pneumoniae</i> presente

plus de 1000 proteines possibles codees, mais n'indique pas elle-meme les proteines pouvant etre utilisees comme antigenes pour une immunisation, une vaccination ou un diagnostic. Cette difficulte est surmontee par l'invention qui fournit un certain nombre de sequences proteiques de *C. pneumoniae* appropriees pour developper et produire des vaccins et/ou pour etablir un diagnostic.

5/3,AB/7 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

00794925

LANTIBIOTIC

LANTIBIOTIQUE

Patent Applicant/Assignee:

UNIVERSITY OF OTAGO, Leith Street, Dunedin, NZ, NZ (Residence), NZ (Nationality), (For all designated states except: US)

BLIS TECHNOLOGIES LIMITED, Level 10, Otago House, 481 Moray Place, Dunedin, NZ, NZ (Residence), NZ (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

TAGG John Robert, 39 Braeview Crescent, Dunedin, NZ, NZ (Residence), AU (Nationality), (Designated only for: US)

DIERKSEN Karen Patricia, c/- 3450 SW Campus Way, Corvallis, OR 97331-8539, US, US (Residence), US (Nationality), (Designated only for: US)

UPTON Mathew, Flat 1, 15 Peacock Street, Christchurch, NZ, NZ (Residence), GB (Nationality), (Designated only for: US)

Legal Representative:

BENNETT Michael Roy (et al) (agent), A J Park, Huddart Parker Building, 6th Floor, 1 Post Office Square, P.O. Box 949, Wellington 6015, NZ,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200127143 A1 20010419 (WO 0127143)

Application: WO 2000NZ197 20001012 (PCT/WO NZ0000197)

Priority Application: NZ 500261 19991012

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 6963

English Abstract

This invention provides an antibacterial protein, salivaricin B.

Salivaricin B is bacteriocidal with respect to, inter alia, *S. pyogenes* and therefore has numerous therapeutic applications. These applications include, but are not limited to, forming part of therapeutic formulations for use in treating or preventing streptococcal infections of the throat.

French Abstract

L'invention concerne une proteine antibacterienne, salivaricine B.

Salivaricine B a une fonction bactericide, y compris vis-a-vis de *S. pyogenes* et possede de ce fait de nombreuses applications therapeutiques. Ces applications comprennent (mais non de facon exclusive) la creation de formulations therapeutiques utilisees dans le traitement ou la prevention des infections de la gorges par des streptocoques.

5/3,AB/8 (Item 6 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT

00780221

PNEUMOCOCCAL VACCINES

VACCINS ANTIPNEUMOCOCCIQUES

Patent Applicant/Assignee:

ERASMUS UNIVERSITEIT ROTTERDAM, Dr. Molewaterplein 50, NL-5015 GE
Rotterdam, NL, NL (Residence), NL (Nationality), (For all designated
states except: US)

Patent Applicant/Inventor:

DE GROOT Ronald, Jan Van Ghestellaan 45, NL-3045 CG Rotterdam, NL, NL
(Residence), NL (Nationality), (Designated only for: US)
HERMANS Peter Wilhelmus Maria, Gortmolenerf 36, NL-2807 EJ Gouda, NL, NL
(Residence), NL (Nationality), (Designated only for: US)

Legal Representative:

PRINS A W, Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague, NL

Patent and Priority Information (Country, Number, Date):

Patent: WO 200112219 A1 20010222 (WO 0112219)

Application: WO 2000NL569 20000814 (PCT/WO NL0000569)

Priority Application: EP 99202640 19990813

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 7578

English Abstract

The invention relates to the use of a protein or a fragment thereof of
S. pneumoniae , its use for the preparation of a vaccine for the
preventive treatment of a S. pneumoniae infection, compositions
comprising protease maturation protein of S. pneumoniae infection, or a
fragment thereof, vaccines comprising said protein or fragment thereof,
use of a nucleic acid sequence encoding for said protein or fragment
thereof, vectors wherein the nucleic acid sequence is brought to
expression and to recombinant protease maturation protein or a fragment
thereof or (functional) homologues thereof and to a method for the
determination of proteins with opsonophagocytic activity and/or in vivo
immunisation and/or in vivo immune protection.

French Abstract

L'invention concerne l'utilisation d'une proteine S. pneumoniae ou d'un
fragment de celle-ci, son utilisation pour la preparation d'un vaccin
pour le traitement preventif d'une infection a S. pneumoniae , des
compositions comprenant la proteine de maturation de protease de S.
pneumoniae ou un fragment de celle-ci, vaccins comprenant ladite
proteine ou un fragment de celle-ci. L'invention porte egalement sur
l'utilisation d'une sequence nucleotidique codant pour ladite proteine ou
ledit fragment de celle-ci, sur des vecteurs dans lesquels l'expression
de la sequence nucleotidique est transformee en proteine de maturation de
protease recombee, en un fragment de celle-ci ou en homologues
(fonctionnels) de celle-ci. L'invention se rapporte encore a un procede
de determination de proteines ayant une activite opsonophagocytiq ue et/ou
d'immunisation in vivo et/ou de protection immunitaire in vivo .

00577589

CYCLODEXTRIN POLYMERS FOR USE AS DRUG CARRIERS

POLYMERES DE CYCLODEXTRINE UTILISES SOUS FORME DE VECTEURS DE MEDICAMENTS

Patent Applicant/Assignee:

KOSAK Ken M,

Inventor(s):

KOSAK Ken M,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200040962 A1 20000713 (WO 0040962)

Application: WO 99US30820 19991227 (PCT/WO US9930820)

Priority Application: US 98223055 19981230

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AU BR CA CN IL IN JP MX AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES

FI FR GB GR IE IT LU MC NL PT SE

Publication Language: English

Fulltext Word Count: 21238

English Abstract

This invention discloses methods for preparing compositions of cyclodextrin polymers for carrying drugs and other active agents. Methods are also disclosed for preparing cyclodextrin polymer carriers that release drugs under controlled conditions. The invention also discloses methods for preparing compositions of cyclodextrin polymer carriers that are coupled to biorecognition molecules for targeting the delivery of drugs to their site of action. The advantages of the water-soluble (or colloidal) cyclodextrin polymer carrier are: 1) drugs can be used that are designed for efficacy without conjugation requirements; 2) it will allow the use of drugs designed solely for efficacy without regard for solubility; 3) unmodified drugs can be delivered as macromolecules and released within the cell; 4) drugs can be targeted by coupling the carrier to biorecognition molecules; 5) synthesis methods are independent of the drug to facilitate multiple drug therapies.

French Abstract

L'invention concerne des techniques permettant de preparer des compositions de polymeres de cyclodextrine qui portent des medicaments et d'autres principes actifs. Ces techniques sont egalement utilisees pour preparer des vecteurs de polymere de cyclodextrine qui liberent des medicaments dans des conditions controlees. L'invention concerne, en outre, des techniques permettant de preparer des vecteurs de polymere de cyclodextrine couples a des molecules de bioreconnaissance, afin de cibler la distribution des medicaments sur leur site d'action. Le vecteur de polymere de cyclodextrine soluble dans l'eau (ou colloidal) presente les avantages suivants: 1) on peut utiliser ces medicaments efficacement concus sans obligation de conjugaison; 2) on peut utiliser ces medicaments concus uniquement pour etre efficaces independamment de leur solubilite; 3) on peut administrer des medicaments non modifies sous forme de macromolecules et les liberer dans la cellule; 4) on peut cibler ces medicaments par couplage du vecteur avec des molecules de reconnaissance; 5) les techniques de synthese sont independantes du medicament, afin de faciliter d'autres therapies a l'aide dudit medicament.

5/3,AB/10 (Item 8 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2005 WIPO/Univentio. All rts. reserv.

00430875

METHOD FOR THE PRODUCTION OF 1,3-PROPANEDIOL BY RECOMBINANT ORGANISMS

PROCEDE DE PRODUCTION DE 1,3-PROPANEDIOL PAR DES ORGANISMES RECOMBINES

Patent Applicant/Assignee:

E I DU PONT DE NEMOURS AND COMPANY,

GENENCOR INTERNATIONAL INC,

GATENBY Anthony Arthur,

HAYNIE Sharon Loretta,

NAGARAJAN Vasantha,
NAIR Ramesh V,
NAKAMURA Charles E,
PAYNE Mark Scott,
PICATAGGIO Stephen Kenneth,
DIAS-TORRES Maria,
HSU Amy Kuang-Hua,
LAREAU Richard D,
TRIMBUR Donald E,
WHITED Gregory M,

Inventor(s):

GATENBY Anthony Arthur,
HAYNIE Sharon Loretta,
NAGARAJAN Vasantha,
NAIR Ramesh V,
NAKAMURA Charles E,
PAYNE Mark Scott,
PICATAGGIO Stephen Kenneth,
DIAS-TORRES Maria,
HSU Amy Kuang-Hua,
LAREAU Richard D,
TRIMBUR Donald E,
WHITED Gregory M,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9821339 A1 19980522
Application: WO 97US20292 19971110 (PCT/WO US9720292)
Priority Application: US 9630601 19961113

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AU BR CA CN ID IL JP KR MX SG US AT BE CH DE DK ES FI FR GB GR IE IT LU
MC NL PT SE

Publication Language: English

Fulltext Word Count: 30753

English Abstract

Recombinant organisms are provided comprising genes encoding glycerol-3-phosphate dehydrogenase, glycerol-3-phosphatase, glycerol dehydratase and 1,3-propanediol oxidoreductase activities useful for the production of 1,3-propanediol from a variety of carbon substrates.

French Abstract

Cette invention concerne des organismes recombinés comportant des gènes codant pour des activités de glycerol-3-phosphate deshydrogenase, de glycerol-3-phosphatase, de glycerol deshydratase et de 1,3-propanediol oxydoreductase. Ces organismes sont utiles a la production de 1,3-propanediol a partir d'une pluralite de substrats carbonés.

5/3,AB/11 (Item 9 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2005 WIPO/Univentio. All rts. reserv.

00353282

BIOCONVERSION OF A FERMENTABLE CARBON SOURCE TO 1,3-PROPANEDIOL BY A SINGLE MICROORGANISM

BIOCONVERSION D'UNE SOURCE DE CARBONE FERMENTESCIBLE EN 1,3-PROPANEDIOL PAR UN SEUL MICRO-ORGANISME

Patent Applicant/Assignee:

E I DU PONT DE NEMOURS AND COMPANY,
GENENCOR INTERNATIONAL INC,
LAFFEND Lisa Anne,
NAGARAJAN Vasantha,
NAKAMURA Charles Edwin,

Inventor(s):

LAFFEND Lisa Anne,
NAGARAJAN Vasantha,
NAKAMURA Charles Edwin,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9635796 A1 19961114
Application: WO 96US6705 19960510 (PCT/WO US9606705)
Priority Application: US 95440293 19950512

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AL AU BB BG BR CA CN CZ EE GE HU IS JP KP KR LK LR LT LV MG MK MN MX NO
NZ PL RO SG SI SK TR TT UA US UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD
RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG
CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 30574

English Abstract

A process is provided for the bioconversion of a carbon substrate to 1,3-propanediol by a single organism utilizing microorganisms containing the genes encoding for an active glycerol or diol dehydratase enzyme by contacting these organisms with a carbon substrate under the appropriate fermentation conditions.

French Abstract

La presente invention concerne un procede de bioconversion d'un substrat de carbone en 1, 3-propanediol par un seul organisme utilisant des micro-organismes qui contiennent les genes codant pour donner un glycerol actif ou une enzyme dehydratase de diol, en mettant ces organismes au contact d'un substrat de carbone dans les conditions de fermentation appropriees.

5/3,AB/12 (Item 1 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2005 European Patent Office. All rts. reserv.

01245487

Pneumococcal vaccines
Pneumokokkus Impfstoffe
Vaccins pneumococciques

PATENT ASSIGNEE:

Erasmus Universiteit Rotterdam, (517671), Dr. Molewaterplein 50, 3015 GE Rotterdam, (NL), (Applicant designated States: all)

INVENTOR:

de Groot, Ronald, Jan van Ghestellaan 45, 3045 CG Rotterdam, (NL)
Hermans, Peter Wilhelmus Maria, Gortmolenerf 36, 2807 EJ Gouda, (NL)

LEGAL REPRESENTATIVE:

Ottevangers, Sietse Ulbe et al (20841), Vereenigde, Postbus 87930, 2508 DH Den Haag, (NL)

PATENT (CC, No, Kind, Date): EP 1075841 A1 010214 (Basic)

APPLICATION (CC, No, Date): EP 99202640 990813;

DESIGNATED STATES: DE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: A61K-039/09; C07K-014/315; C12N-015/31;

C07K-016/12; A61P-031/04

ABSTRACT EP 1075841 A1

The invention relates to the use of a protein or a fragment thereof of *S. pneumoniae*, its use for the preparation of a vaccine for the preventive treatment of a *S. pneumoniae* infection, compositions comprising protease maturation protein of *S. pneumoniae* or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant protease maturation protein or a fragment thereof.

ABSTRACT WORD COUNT: 86

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200107	457
SPEC A	(English)	200107	5155
Total word count - document A			5612
Total word count - document B			0
Total word count - documents A + B			5612

5/3,AB/13 (Item 2 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2005 European Patent Office. All rts. reserv.

01132827
NOVEL METHODS FOR THE IDENTIFICATION OF LIGAND AND TARGET BIOMOLECULES
NEUE METHODEN ZUM AUFFINDEN VON LIGANDEN- UND ZIEL-BIOMOLEKULEN
NOUVELLES TECHNIQUES D'IDENTIFICATION DE LIGAND ET DE BIOMOLECULES CIBLES
PATENT ASSIGNEE:

Inoxell A/S, (3937780), Kogle Alle 5, 2970 Hoersholm, (DK), (Proprietor
designated states: all)

INVENTOR:

HALKIER, Torben, Lyngvej 5, DK-2680 Solrod Strand, (DK)
JESPERSEN, Lene, Sorupvej 48, DK-3480 Fredensborg, (DK)
JENSEN, Allan, Praestemosevej 1, DK-3480 Fredensborg, (DK)

PATENT (CC, No, Kind, Date): EP 1098991 A1 010516 (Basic)
EP 1098991 B1 020911
WO 2000005406 000203

APPLICATION (CC, No, Date): EP 99932689 990716; WO 99DK408 990716

PRIORITY (CC, No, Date): DK 98956 980720; US 94868 P 980729

DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;
LU; MC; NL; PT; SE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

RELATED DIVISIONAL NUMBER(S) - PN (AN):

(EP 2002076171)

INTERNATIONAL PATENT CLASS: C12Q-001/68; C12N-015/10

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200237	1550
CLAIMS B	(German)	200237	1426
CLAIMS B	(French)	200237	1778
SPEC B	(English)	200237	21412
Total word count - document A			0
Total word count - document B			26166
Total word count - documents A + B			26166

5/3,AB/14 (Item 1 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)
(c) 2005 The Gale Group. All rts. reserv.

09176370 Supplier Number: 80023947
INGREDIENTS.(directory of food ingredient companies)(Directory)
Food Processing, v62, n10, p35
Oct, 2001
Language: English Record Type: Fulltext
Article Type: Directory
Document Type: Magazine/Journal; Trade
Word Count: 36874

5/3,AB/15 (Item 1 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB
(c)2005 The Gale Group. All rts. reserv.

14030230 SUPPLIER NUMBER: 80023948 (USE FORMAT 7 OR 9 FOR FULL TEXT)
NUTRACEUTICAL COMPANIES.(directory)(Directory)

Food Processing, 62, 10, 69

Oct, 2001

DOCUMENT TYPE: Directory

ISSN: 0015-6523

LANGUAGE: English

RECORD TYPE: Fulltext

WORD COUNT: 2323 LINE COUNT: 00226

?

xecuting TA40273423

Hiligh option is not available in file(s) 398, 399

HILIGHT set on as '%'

S1 180606 LACTOBACILLUS

? s s1 and protease (1w) maturation (1w) protein

Processing

Processed 10 of 60 files ...

Completed processing all files

180606 S1

707173 PROTEASE

662519 MATURATION

15747110 PROTEIN

44 PROTEASE(1W)MATURATION(1W)PROTEIN

S2 12 S1 AND PROTEASE (1W) MATURATION (1W) PROTEIN

? rd

>>>Duplicate detection is not supported for File 398.

>>>Duplicate detection is not supported for File 654.

>>>Duplicate detection is not supported for File 349.

>>>Duplicate detection is not supported for File 348.

>>>Duplicate detection is not supported for File 340.

>>>Duplicate detection is not supported for File 390.

>>>Duplicate detection is not supported for File 347.

>>>Duplicate detection is not supported for File 446.

>>>Duplicate detection is not supported for File 342.

>>>Duplicate detection is not supported for File 345.

>>>Duplicate detection is not supported for File 181.

>>>Duplicate detection is not supported for File 324.

>>>Duplicate detection is not supported for File 391.

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 767.

>>>Duplicate detection is not supported for File 344.

>>>Duplicate detection is not supported for File 286.

>>>Records from unsupported files will be retained in the RD set.

...completed examining records

S3 12 RD (unique items)

? t s3/3,ab/1-12

>>>No matching display code(s) found in file(s): 65, 135, 181, 342, 345,
390-391, 398, 446, 767

3/3,AB/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0009999546 BIOSIS NO.: 199598467379

Nucleotide sequence and characterization of peb4A encoding an antigenic
protein in *Campylobacter jejuni*

AUTHOR: Burucoa C (Reprint); Fremaux Z; Pei Z; Tummuru M; Blaser M J;
Cenatiempo Y; Fauchere J L

AUTHOR ADDRESS: Laboratoire de Microbiologie A, CHU La Miletrie, BP 577,
86021 Poitiers, France**France

JOURNAL: Research in Microbiology 146 (6): p467-476 1995 1995

ISSN: 0923-2508

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The 29-kDa protein PEB4, a major antigen of *Campylobacter jejuni*, is present in all *C. jejuni* strains tested and elicits an antibody response in infected patients. By screening a lambda-gt11 library of chromosomal DNA fragments of *C. jejuni* strain 81-176 in *Escherichia coli* Y1090 cells with antibody raised against purified PEB4, a recombinant phage with a 2-kb insert expressing an immunoreactive protein of 29 kDa was isolated. DNA sequence analysis revealed that the insert contains two complete open reading frames ORF-A and ORF-B. ORF-A (peb4A) encodes a 273-residue protein with a calculated molecular mass of 30,460 daltons. The deduced amino acid sequence, composition and pI of the recombinant mature protein are similar to those determined for purified PEB4. The

first 21 residues resemble a signal peptide. Gene bank searches indicated 33.7% identity with protein export protein PrsA of Bacillus subtilis and 23.8% identity with %protease% %maturation% %protein% precursor PrtM of Lactococcus lactis. PCR experiments indicate that peb4A is highly conserved among C. jejuni strains. ORF-B begins 2 bp after the last codon of peb4A and encodes a putative protein of 353 residues with 63.4% identity with E. coli fructose 1,6-biphosphate aldolase. The sequence arrangement suggests that these two genes form an operon.

3/3,AB/2 (Item 1 from file: 398)
DIALOG(R)File 398:Chemsearch
(c) 2005 Amer.Chem.Society All rts. reserv.

CAS REGISTRY NUMBER: 647192-71-0
MOLECULAR FORMULA: Unknown
CA NAME(S):
HP=Protease maturation protein precursor (Lactobacillus johnsonii strain NCC533) (9CI)
SYNONYMS: GenBank AAS09786; GenBank AAS09786 (Translated from: GenBank AE017206)

3/3,AB/3 (Item 2 from file: 398)
DIALOG(R)File 398:Chemsearch
(c) 2005 Amer.Chem.Soc. All rts. reserv.

CAS REGISTRY NUMBER: 647189-30-8
MOLECULAR FORMULA: Unknown
CA NAME(S):
HP=Protease maturation protein precursor (Lactobacillus johnsonii strain NCC533) (9CI)
SYNONYMS: GenBank AAS09446; GenBank AAS09446 (Translated from: GenBank AE017205)

3/3,AB/4 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005386990
Derwent Accession: 2003-167404
Bacterial ghosts provided with antigens
Inventor: Leenhouts, Cornelis, INV
Ramasamy, Ranjan, INV
Steen, Anton, INV
Kok, Jan, INV
Buist, Girbe, INV
Kuipers, Oscar, INV

Correspondence Address: TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030186851	A1	20031002	US 2002318675	20021213
Continuation	UNKNOWN			WO 2002NL383	20020611
Priority				EP 2001202239	20010611

Fulltext Word Count: 17239

Abstract:

Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such

as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

3/3,AB/5 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) Format only 2005 The Dialog Corp. All rts. reserv.

0005377142

Derwent Accession: 2003-167404

Method to provide bacterial ghosts provided with antigens

Inventor: Leenhouts, Cornelis, INV

Ramasamy, Ranjan, INV

Steen, Anton, INV

Kok, Jan, INV

Buist, Girbe, INV

Kuipers, Oscar, INV

Correspondence Address: TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT,
84110, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20030180816	A1	20030925	US 2002321857	20021216
Continuation	UNKNOWN			WO 2002NL383	20020611
Priority				EP 2001202239	20010611

Fulltext Word Count: 17864

Abstract:

Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.

3/3,AB/6 (Item 1 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

01097829

CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES

GENOMES DE STREPTOCOQUES CONSERVES OU SPECIFIQUES

Patent Applicant/Assignee:

CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US
(Residence), US (Nationality), (For all designated states except: US)

THE INSTITUTE FOR GENOMIC RESEARCH, 9712 Medical Center Drive, Rockville,
MD 20850, US, US (Residence), US (Nationality), (For all designated
states except: US)

Patent Applicant/Inventor:

TETTELIN Herve, c/o The Institute for Genomic Research, 9712 Medical
Center Drive, Rockville, MD 20850, US, US (Residence), BE (Nationality)
, (Designated only for: US)

MASIGNANI Vega, c/o Chiron Corporation, 4560 Horton Street, Emeryville,
CA 94608, US, IT (Residence), IT (Nationality), (Designated only for:
US)

Legal Representative:

HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property

R338, P.O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200418646 A2 20040304 (WO 0418646)
Application: WO 2003US26827 20030826 (PCT/WO US03026827)
Priority Application: US 2002406237 20020826; US 2002406676 20020827; US
2002406757 20020828

Parent Application/Grant:

Related by Continuation to: US 2002406237 20020826 (CIP); US 2002406676
20020827 (CIP); US 2002406757 20020828 (CIP)

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD
SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE
SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 297825

English Abstract

The invention relates to polynucleotides which are conserved or specific
to one or more species of Streptococcus, Streptococcus species serotypes,
and/or serotype isolates. In particular, the invention relates to
polynucleotides from Streptococcus which are conserved or specific to one
or more of the species of *S. pneumoniae* ("pneumococcus" or "*S. pn.*"), *S.*
pyogenes ("group A streptococcus" or "GAS"), and *S. agalactiae* ("group B
streptococcus" or "GBS"). The invention further relates to
polynucleotides which are conserved or specific to one or more
Streptococcal species serotypes, such as GBS serotypes Ia, Ib, II, III,
IV, V, VI, VII, and VIII. The invention still further relates to
polynucleotides which are conserved or specific to one or more clinical
isolates of a Streptococcus species.

French Abstract

Cette invention concerne des polynucleotides conserves ou specifiques
d'une ou de plusieurs especes de streptocoques, de serotypes d'especes de
streptocoques et/ou d'isolats de serotypes. L'invention concerne en
particulier des polynucleotides de streptocoques qui sont conservee ou
specifiques d'une ou de plusieurs especes de *S. pneumoniae*
("pneumococcus" ou "*S. pn.*"), *S. pyogenes* ("streptocoques du
groupe A" ou "GAS"), et *S. agalactiae* ("streptocoques du groupe B
" ou "GBS"). L'invention concerne egalement des polynucleotides qui sont
conserves ou specifiques d'un ou de plusieurs serotypes d'especes
streptococciques, tels que les serotypes GBS Ia, Ib, II, III, IV, V, VI,
VII, et VIII. L'invention concerne en outre des polynucleotides qui sont
conserves ou specifiques d'un ou de plusieurs isolats cliniques d'une
espece de streptocoque.

3/3,AB/7 (Item 2 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2005 WIPO/Univentio. All rts. reserv.

00968329

METHODS FOR BINDING ACMA-TYPE PROTEIN ANCHOR FUSIONS TO CELL-WALL MATERIAL
OF MICRO-ORGANISMS

TECHNIQUE AMELIOREE PERMETTANT DE FIXER DES FUSIONS D'ANCRAGE DE PROTEINES
DE TYPE ACMA A LA PAROI CELLULAIRE DE MICRO-ORGANISMES

Patent Applicant/Assignee:

APPLIED NANOSYSTEMS B V, Postbus 100, NL-9700 AC Groningen, NL, NL

(Residence), NL (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

LEENHOUTS Cornelis Johannes, Tussenkoelen 6, NL-9753 KX Haren, NL, NL

(Residence), NL (Nationality), (Designated only for: US)
RAMASAMY Ranjan, 137/3 Kirula Road, Colombo 05, LK, LK (Residence), LK
(Nationality), (Designated only for: US)
STEEN Anton, Zonland 143, NL-9734 BR Groningen, NL, NL (Residence), NL
(Nationality), (Designated only for: US)
KOK Jan, Van Hamelstraat 34, NL-9714 HL Groningen, NL, NL (Residence), NL
(Nationality), (Designated only for: US)
BUIST Girbe, Noordbroeksterstraat 88, NL-9611 BN Sappemeer, NL, NL
(Residence), NL (Nationality), (Designated only for: US)
KUIPERS Oscar Paul, Lepelaar 95, NL-9728 XG Groningen, NL, NL (Residence)
, NL (Nationality), (Designated only for: US)

Legal Representative:

PRINS A W (agent), c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The
Hague, NL,

Patent and Priority Information (Country, Number, Date):

Patent: WO 2002101026 A2-A3 20021219 (WO 02101026)

Application: WO 2002NL383 20020611 (PCT/WO NL02000383)

Priority Application: EP 2001202239 20010611

Designated States:

(Protection type is "patent" unless otherwise stated - for applications
prior to 2004)

AE AG AL AM AT (utility model) AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ (utility model) CZ DE (utility model) DE DK (utility model) DK DM
DZ EC EE (utility model) EE ES FI (utility model) FI GB GD GE GH GM HR HU
ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK (utility model) SK SL TJ TM TN
TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 15714

English Abstract

The invention provides a method for binding of a proteinaceous substance
to cell-wall material of a Gram-positive bacterium, said substance
comprising an AcmA cell wall binding domain or homolog or functional
derivative thereof, said method comprising treating said cell-wall
material with a solution capable of removing a cell-wall component such
as a protein, (lipo) teichoic acid or carbohydrate from said
cell-wall-material and contacting said substance with said cell-wall
material.

French Abstract

La presente invention concerne une technique permettant d'ameliorer la
liaison d'une substance proteique a la paroi cellulaire d'une bacterie
Gram positif, cette substance comprenant un domaine de fixation de paroi
de cellule AcmA ou un homologue ou un derive fonctionnel de celui-ci.
Cette technique consiste a traiter cette paroi cellulaire avec une
solution capable de retirer un element de cette paroi cellulaire tel
qu'une proteine, un acide (lipo)teichoique ou un element glucidique de
cette paroi et de mettre en contact cette substance avec cette paroi
cellulaire.

3/3,AB/8 (Item 3 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2005 WIPO/Univentio. All rts. reserv.

00901997

NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A & B

ACIDES NUCLEIQUES ET PROTEINES DERIVES DES GROUPES DE STREPTOCOQUES A ET B

Patent Applicant/Assignee:

CHIRON S P A, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT
(Nationality), (For all designated states except: US)

THE INSTITUTE FOR GENOMIC RESEARCH, 9712 Medical Center Drive, Rockville,

MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

TELFORD John, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT
(Residence), GB (Nationality), (Designated only for: US)
MASIGNANI Vega, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT
(Residence), IT (Nationality), (Designated only for: US)
MARGARIT Y ROS Immaculada, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena
, IT, IT (Residence), IT (Nationality), (Designated only for: US)
GRANDI Guido, Chiron S.p.a, Via Fiorentina, 1, I-53100 Siena, IT, IT
(Residence), IT (Nationality), (Designated only for: US)
FRASER CLAIRE, The Institute for Genomic Research, 9712 Medical Center
Drive, Rockville, MD 20850, US, US (Residence), US (Nationality),
(Designated only for: US)
TETTELIN Herve, The Institute for Genomic Research, 9712 Medical Center
Drive, Rockville, MD 20850, US, US (Residence), BE (Nationality),
(Designated only for: US)

Legal Representative:

HALLYBONE Huw George (et al) (agent), Carpmiels & Ransford, 43 Bloomsbury
Square, London WC1A 2RA, GB,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200234771 A2-A3 20020502 (WO 0234771)
Application: WO 2001GB4789 20011029 (PCT/WO GB0104789)
Priority Application: GB 200026333 20001027; GB 200028727 20001124; GB
20015640 20010307

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ
EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 1058437

English Abstract

The invention provides proteins from group B streptococcus (*Streptococcus agalactiae*) and group A streptococcus (*Streptococcus pyogenes*), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

French Abstract

Cette invention se rapporte a des proteines derivees du streptocoque de groupe B (*Streptococcus agalactiae*) et du streptocoque de groupe A (*Streptococcus pyogenes*), y compris des sequences d'acides amines et les sequences de nucleotides correspondantes. On produit des donnees qui montrent que ces proteines constituent des antigenes utiles pour des vaccins, des compositions immunogenes et/ou des diagnostics. Ces proteines constituent egalement des cibles pour des antibiotiques.

3/3,AB/9 (Item 4 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

00780221

PNEUMOCOCCAL VACCINES

VACCINS ANTIPNEUMOCOCCIQUES

Patent Applicant/Assignee:

ERASMUS UNIVERSITEIT ROTTERDAM, Dr. Molewaterplein 50, NL-5015 GE
Rotterdam, NL, NL (Residence), NL (Nationality), (For all designated

states except: US)
Patent Applicant/Inventor:
DE GROOT Ronald, Jan Van Ghestellaan 45, NL-3045 CG Rotterdam, NL, NL
(Residence), NL (Nationality), (Designated only for: US)
HERMANS Peter Wilhelmus Maria, Gortmolenerf 36, NL-2807 EJ Gouda, NL, NL
(Residence), NL (Nationality), (Designated only for: US)

Legal Representative:

PRINS A W, Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague, NL
Patent and Priority Information (Country, Number, Date):

Patent: WO 200112219 A1 20010222 (WO 0112219)
Application: WO 2000NL569 20000814 (PCT/WO NL0000569)
Priority Application: EP 99202640 19990813

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT
LU LV MA MD ME MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
TR TT TZ UA UG US UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 7578

English Abstract

The invention relates to the use of a protein or a fragment thereof of *S. pneumoniae*, its use for the preparation of a vaccine for the preventive treatment of a *S. pneumoniae* infection, compositions comprising %protease% %maturation% %protein% of *S. pneumoniae* infection, or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant %protease% %maturation% %protein% or a fragment thereof or (functional) homologues thereof and to a method for the determination of proteins with opsonophagocytic activity and/or in vivo immunisation and/or in vivo immune protection.

French Abstract

L'invention concerne l'utilisation d'une proteine *S. pneumoniae* ou d'un fragment de celle-ci, son utilisation pour la preparation d'un vaccin pour le traitement preventif d'une infection a *S. pneumoniae*, des compositions comprenant la proteine de maturation de protease de *S. pneumoniae* ou un fragment de celle-ci, vaccins comprenant ladite proteine ou un fragment de celle-ci. L'invention porte egalement sur l'utilisation d'une sequence nucleotidique codant pour ladite proteine ou ledit fragment de celle-ci, sur des vecteurs dans lesquels l'expression de la sequence nucleotidique est transformee en proteine de maturation de protease recombinnee, en un fragment de celle-ci ou en homologues (fonctionnels) de celle-ci. L'invention se rapporte encore a un procede de determination de proteines ayant une activite opsonophagocytiq ue et/ou d'immunisation in vivo et/ou de protection immunitaire in vivo .

3/3,AB/10 (Item 5 from file: 349)
DIALOG(R)File 349:PCT FULLTEXT
(c) 2005 WIPO/Univentio. All rts. reserv.

00336983

METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED
EVENTS, INCLUDING HIV TRANSMISSION
PROCEDES ET COMPOSITIONS POUR EMPECHER CERTAINS PHENOMENES ASSOCIES AVEC LA
FUSION AVEC LA MEMBRANE, EN PARTICULIER LA TRANSMISSION DU VIH

Patent Applicant/Assignee:

DUKE UNIVERSITY,
TRIMERIS INC,

Inventor(s) :

BOLOGNESI Dani P,
MATTHEWS Thomas J,
WILD Cart T,
BARNEY Shawn O'Lin,
LAMBERT Dennis M,
PETTEWAY Stephen R Jr,
LANGLOIS Alphonse J,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9619495 A1 19960627
Application: WO 95US16733 19951220 (PCT/WO US9516733)
Priority Application: US 94107 19941220; US 95896 19950606

Designated States:

(Protection type is "patent" unless otherwise stated - for applications prior to 2004)

AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LS LT
LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ VN KE LS MW SD
SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 203630

English Abstract

The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

French Abstract

La presente invention concerne des peptides qui presentent une activite importante contre les retrovirus. Les peptides de l'invention comprennent le peptide DP178 (SEQ ID:1) correspondant aux acides amines 638 a 673 de la proteine VIH-1LAI gp41 et des fragments, analogues et homologues de DP178. L'invention concerne en outre l'utilisation de ces peptides comme inhibiteurs de la transmission a des cellules non infectees de retrovirus humains ou non humains, en particulier du VIH.

3/3,AB/11 (Item 1 from file: 348)
DIALOG(R)File 348:EUROPEAN PATENTS
(c) 2005 European Patent Office. All rts. reserv.

01245487

Pneumococcal vaccines
Pneumokokkus Impfstoffe
Vaccins pneumococciques

PATENT ASSIGNEE:

Erasmus Universiteit Rotterdam, (517671), Dr. Molewaterplein 50, 3015 GE Rotterdam, (NL), (Applicant designated States: all)

INVENTOR:

de Groot, Ronald, Jan van Ghestellaan 45, 3045 CG Rotterdam, (NL)
Hermans, Peter Wilhelmus Maria, Gortmolenerf 36, 2807 EJ Gouda, (NL)

LEGAL REPRESENTATIVE:

Ottevangers, Sietse Ulbe et al (20841), Vereenigde, Postbus 87930, 2508 DH Den Haag, (NL)

PATENT (CC, No, Kind, Date): EP 1075841 A1 010214 (Basic)

APPLICATION (CC, No, Date): EP 99202640 990813;

DESIGNATED STATES: DE

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: A61K-039/09; C07K-014/315; C12N-015/31;

C07K-016/12; A61P-031/04

ABSTRACT EP 1075841 A1

The invention relates to the use of a protein or a fragment thereof of *S. pneumoniae*, its use for the preparation of a vaccine for the

preventive treatment of a *S. pneumoniae* infection, compositions comprising %protease% %maturation% %protein% of *S. pneumoniae* or a fragment thereof, vaccines comprising said protein or fragment thereof, use of a nucleic acid sequence encoding for said protein or fragment thereof, vectors wherein the nucleic acid sequence is brought to expression and to recombinant %protease% %maturation% %protein% or a fragment thereof.

ABSTRACT WORD COUNT: 86

NOTE:

Figure number on first page: NONE

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200107	457
SPEC A	(English)	200107	5155
Total word count - document A			5612
Total word count - document B			0
Total word count - documents A + B			5612

3/3,AB/12 (Item 1 from file: 47)

DIALOG(R)File 47:Gale Group Magazine DB(TM)

(c) 2005 The Gale group. All rts. reserv.

06371065 SUPPLIER NUMBER: 76997548 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Complete Genome Sequence of a Virulent Isolate of *Streptococcus pneumoniae*. (research) (Illustration) (Statistical Data Included)

Tettelin, Herve; Nelson, Karen E.; Paulsen, Ian T.; Eisen, Jonathan A.; Read, Timothy D.; Peterson, Scott; Heidelberg, John; DeBoy, Robert T.; Haft, Daniel H.; Dodson, Robert J.; Durkin, A. Scott; Gwinn, Michelle; Kolonay, James F.; Nelson, William C.; Peterson, Jeremy D.; Umayam, Lowell A.; White, Owen; Salzberg, Steven L.; Lewis, Matthew R.; Radune, Diana; Holtzapple, Erik; Khouri, Hoda; Wolf, Alex M.; Utterback, Terry R.; Hansen, Cheryl L; McDonald, Lisa A.; Feldblyum, Tamara V.; Angiuoli, Samuel; Dickinson, Tanja; Hickey, Erin K.; Holt, Ingeborg E.; Loftus, Brendan J.; Yang, Fan; Smith, Hamilton O.; Venter, J. Craig; Dougherty, Brian A.; Morrison, Donald A.; Hollingshead, Susan K.; Fraser, Claire M.

Science, 293, 5529, 498

July 20, 2001

DOCUMENT TYPE: Illustration Statistical Data Included ISSN: 0036-8075

LANGUAGE: English RECORD TYPE: Fulltext; Abstract

WORD COUNT: 6269 LINE COUNT: 00667

AUTHOR ABSTRACT: The 2,160,837--base pair genome sequence of an isolate of *Streptococcus pneumoniae*, a Gram-positive pathogen that causes pneumonia, bacteremia, meningitis, and otitis media, contains 2236 predicted coding regions; of these, 1440 (64%) were assigned a biological role. Approximately 5% of the genome is composed of insertion sequences that may contribute to genome rearrangements through uptake of foreign DNA. Extracellular enzyme systems for the metabolism of polysaccharides and hexosamines provide a substantial source of carbon and nitrogen for *S. pneumoniae* and also damage host tissues and facilitate colonization. A motif identified within the signal peptide of proteins is potentially involved in targeting these proteins to the cell surface of low--guanine/cytosine (GC) Gram-positive species. Several surface-exposed proteins that may serve as potential vaccine candidates were identified. Comparative genome hybridization with DNA arrays revealed strain differences in *S. pneumoniae* that could contribute to differences in virulence and antigenicity.

?